Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Abbott commences phase III bardoxolone methyl trial

Abbott commences phase III bardoxolone methyl trial

17th June 2011

Abbott is commencing a clinical study of its investigational drug bardoxolone methyl, in association with partner Reata Pharmaceuticals.

The pivotal phase III Beacon trial is to evaluate the compound as a therapy option for chronic kidney disease and type 2 diabetes among around 1,600 patients based at 300 sites worldwide.

Results from the placebo-controlled study are expected in 2013, with the manufacturers aiming to demonstrate the drug's efficacy in helping patients to delay progression to end-stage renal disease.

It is hoped that the data will reinforce the positive results noted in the earlier phase II Beam study, which showed bardoxolone methyl's effectiveness in improving kidney function in patients.

Dr Pablo Pergola, director of Renal Associates' research division in San Antonio, Texas, said: "We look forward to further evaluating the drug candidate's effects on clinical outcomes in this patient population."

Earlier this month, Abbott published positive interim data from a phase III trial of levodopa-carbidopa intestinal gel, its new treatment for Parkinson's disease.ADNFCR-8000103-ID-800582605-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.